CA 125, a New Prognostic Marker for Aggressive NHL.

Area of Science:

• Oncology
• Hematology
• Biochemistry

Background:

• Non-Hodgkin's lymphoma (NHL), particularly diffuse large B cell lymphoma (DLBCL), is an aggressive hematologic malignancy.
• Biomarkers such as cancer antigen 125 (CA 125), lactate dehydrogenase (LDH), and beta-2 microglobulin (β2m) are investigated for their clinical utility in DLBCL.
• Understanding the prognostic significance of these markers aids in patient management and treatment stratification.

Purpose of the Study:

• To evaluate the diagnostic and follow-up value of CA 125 in patients with aggressive NHL.
• To compare the prognostic value of CA 125 with established markers like LDH and β2m.
• To assess the correlation of CA 125 with clinical prognostic factors in DLBCL.

Main Methods:

• A cohort of 78 newly diagnosed DLBCL patients (age 18-60, WHO performance status 0-II) and 20 healthy controls were studied.
• Serum levels of CA 125, LDH, and β2m were measured at diagnosis.
• Patients received the CHOP chemotherapy regimen for 6 cycles; treatment response and survival were monitored.

Main Results:

• Significantly higher CA 125 and LDH levels were observed in DLBCL patients compared to controls (p=0.031 and p=0.009, respectively).
• CA 125 elevation correlated with advanced stage, bulky disease, extranodal involvement, and effusion (p<0.001).
• Elevated CA 125, LDH, and β2m levels were associated with significantly decreased overall survival and disease-free survival (p<0.001 for CA 125).

Conclusions:

• CA 125 is a valuable biomarker in DLBCL, correlating with disease burden and stage.
• Elevated CA 125 and LDH levels are significant predictors of poor prognosis in DLBCL patients.
• Initial CA 125 measurement provides important prognostic information, aiding in risk stratification and treatment decisions.